Seattle Genetics, an emerging multi-product, global biotechnology company, develops and commercializes transformative cancer-targeting therapies. ADCETRIS® (brentuximab vedotin) utilizes the company’s industry-leading antibody-drug conjugate (ADC) technology and is currently approved for the treatment of multiple CD30-expressing lymphomas. Beyond ADCETRIS, the company has established a robust pipeline of novel targeted therapies, including three in late-stage development to address significant unmet needs. Seattle Genetics is headquartered in the Bothell, Washington, and has European operations located in Switzerland.
21823 30th Drive Southeast
Bothell, Washington 98021